Wayfair Inc.

Held by 2 specialist biotech funds

Fund Holdings

Driehaus Capital Eventide Asset Management

AI Signal

**Signal Note: Driehaus Capital Initiates Wayfair Position** This move is notable primarily for what it *isn't*—a biotech position.

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$436K

1 fund

Feb 17, 2026

$14.4M

1 fund

+3208% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 143,638Value: $14.4M

**Signal Note: Driehaus Capital Initiates Wayfair Position** This move is notable primarily for what it *isn't*—a biotech position. Driehaus's $14.4M entry into Wayfair (home furnishings e-commerce) suggests either tactical portfolio rebalancing or conviction in retail/consumer discretionary amid improving macro conditions, representing a notable departure from their biotech-heavy mandate. Without disclosed catalyst-specific commentary, the position appears driven by valuation/secular timing rather than company-specific biotech developments.

Eventide Asset ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AXON2 funds NVDA2 funds VEEV2 funds VCYT2 funds LBRT2 funds RMBS2 funds UNP2 funds LITE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide's Wayfair Entry Signals Valuation Reset** This $436K position in W represents a notable departure for a values-focused biotech-concentrated fund, suggesting conviction in Wayfair's operational inflection rather than sector rotation. The initiation likely reflects confidence in margin expansion initiatives and inventory normalization post-pandemic, though this trade sits outside Eventide's traditional healthcare thesis and warrants monitoring for potential profit-taking volatility.